Kanopas 10 mg Tablet is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist indicated for use in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). It is designed to reduce the risk of progressive kidney damage and serious cardiovascular complications. By targeting mineralocorticoid receptor overactivation, Kanopas 10 mg helps slow disease progression and improve long-term renal and cardiovascular outcomes.

Kanopas 10 mg works beyond conventional supportive therapy by addressing inflammation and fibrosis in kidney and cardiovascular tissues, making it an important option in the comprehensive management of diabetic kidney disease.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Kanopas 10 mg is indicated to reduce the risk of:

• Sustained decline in estimated glomerular filtration rate (eGFR)

• End-stage kidney disease

• Cardiovascular death

• Non-fatal myocardial infarction

• Hospitalization for heart failure

in adult patients with chronic kidney disease associated with type 2 diabetes.

Dosage and Administration

Before Initiation

• Measure serum potassium levels and eGFR prior to starting therapy

• Do not initiate Kanopas 10 mg if serum potassium is greater than 5.0 mEq/L

Recommended Starting Dose (based on eGFR)

• eGFR ≥60 mL/min/1.73 m²: 20 mg once daily

• eGFR ≥25 to <60 mL/min/1.73 m²: 10 mg once daily

• eGFR <25 mL/min/1.73 m²: Not recommended

For patients unable to swallow whole tablets, the tablet may be crushed and mixed with water or soft foods such as applesauce and taken immediately.

Drug Interactions

• Strong CYP3A4 Inhibitors: Concomitant use is contraindicated as it significantly increases Kanopas exposure and the risk of adverse reactions. Avoid grapefruit and grapefruit juice.

• Moderate or Weak CYP3A4 Inhibitors: May increase drug exposure. Monitor serum potassium closely during initiation or dose adjustment.

• Strong or Moderate CYP3A4 Inducers: May reduce Kanopas effectiveness. Concomitant use should be avoided.

Contraindications

Kanopas 10 mg is contraindicated in patients:

• Receiving concomitant treatment with strong CYP3A4 inhibitors

• With adrenal insufficiency

Side Effects

The most clinically significant adverse reaction associated with Kanopas 10 mg is:

• Hyperkalemia

Regular monitoring is essential to minimize risk.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Kanopas 10 mg can cause hyperkalemia, particularly in patients with reduced kidney function or elevated baseline potassium

• Measure serum potassium and eGFR before initiation and periodically during treatment

• More frequent monitoring is required in high-risk patients or those on medications that increase serum potassium

Mode of Action

Kanopas 10 mg is a nonsteroidal, selective mineralocorticoid receptor antagonist. It blocks MR-mediated sodium reabsorption and prevents MR overactivation in epithelial tissues such as the kidneys and nonepithelial tissues including the heart and blood vessels. This action helps reduce inflammation and fibrosis without significant interaction with androgen, progesterone, estrogen, or glucocorticoid receptors.

Use in Special Populations

• Pregnancy: No adequate human data; animal studies show developmental toxicity. Use only if potential benefit justifies risk.

• Breastfeeding: Avoid during treatment and for 1 day after the last dose.

• Pediatric Use: Safety and efficacy not established in patients below 18 years.

• Geriatric Use: No dose adjustment required.

• Hepatic Impairment: Avoid in severe hepatic impairment (Child-Pugh C). Monitor serum potassium closely in moderate impairment.

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.